Myxedema Coma Market Share

North American Market Forecast

Myxedema coma market in North America is predicted to account for the largest share of 38% by the end of 2036 impelled by the growing prevalence of obesity. In the USA, obesity is a significant public health issue, which affects over 30% of Americans. Moreover, patients with obesity have a higher chance of developing hypothyroidism which may lead to myxedema coma if left untreated. According to the estimates, during the COVID-19 pandemic, the obesity rate in the U.S. increased by over 2% in 2021.

APAC Market Statistics

The Asia Pacific myxedema coma market is estimated to be the second largest, during the forecast timeframe led by a higher prevalence of iodine deficiency. One of the most frequent causes of hypothyroidism in the globe is iodine deficiency, which is highly prevalent in several nations in the Asia Pacific region such as South and Southeast Asia. As a result, iodine supplementation and thyroid hormone replacement therapy are becoming popular in the region.

For instance, no state in India is immune to iodine deficiency, and more than 150 million people are in danger' of developing iodine deficiency.